Next we tested whether adoptive immunotherapy would exert immune pressure to impair tumour development in the tolerogenic 11c.OVA environment and whether PD-1/PD-L1 blockade might enhance this using a dose of tumour cells modelling a high pre-existing tumour burden. This evidence concerns the gene CD274 and neoplasm.